This CE activity is derived from content presented at the 2021 ASHP Midyear Clinical Meeting & Exhibition. The expert faculty, led by Dr. John Fanikos, will highlight the pharmacist’s role in treating patients with cardio renal metabolic disorders, utilizing SGLT2 receptor inhibitor therapeutics. The faculty will start by providing an overview of the interconnection of cardio renal metabolic disorders, and the science of SGLT2 receptor inhibitors. Following, recent clinical trial data for SGLT2 inhibitor therapeutics will be analyzed. The faculty will conclude with a review of the optimal role of the pharmacist in the applications of SGLT2 receptor inhibitors to manage type 2 diabetes, reduce hospital admissions for heart failure, reduce cardiovascular deaths, and slowing the progression of chronic kidney disease, especially in the pandemic era of COVID-19. Upon completion of this activity, pharmacists will gain better insight into the utilization of SGLT2 inhibitor therapeutics for the care of their patients with cardio renal metabolic disorders.
Pharmacists and other HCPs who care for patients with cardio renal metabolic disorders
- Understand the interconnection of cardio renal metabolic disorders and the science of SGLT2 receptor inhibitors
- Analyze recent clinical trial data for SGLT2i therapeutics targeting type 2 diabetes, heart failure, and chronic kidney disease
- Review the optimal role of pharmacists in the applications of SGLT2 receptor inhibitors to manage type 2 diabetes, reduce hospital admissions for heart failure, reduce cardiovascular deaths, and slowing the progression of chronic kidney disease, especially in the pandemic era of COVID-19
I. The Interconnection of Cardio Renal Metabolic Disorders and the Science of SGLT2 Receptor Inhibitors – John Fanikos, RPh, MBA
II. Clinical Trial Update for SGLT2i Therapeutics Targeting Type 2 Diabetes, Heart Failure, and Chronic Kidney Disease – Leo Buckley, PharmD
III. The Pharmacist’s Role in the Application of SGLT2 Receptor Inhibitors to Manage T2D, Reducing Hospital Admissions for HF, Reducing CVD Deaths, and Slowing the Progression of CKD, Especially in the Pandemic Era of COVID-19 – Craig Beavers, PharmD
John Fanikos, RPh, MBA
Assistant Professor of Clinical Pharmacy Practice
Massachusetts College of Pharmacy
Director of Pharmacy Business and Financial Services
Brigham and Women’s Hospital
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|John Fanikos, RPh, MBA
|Consultant/Advisor: Alexion Pharmaceuticals, Inc.; Boehringer Ingelheim International GmBH; Pacira Pharmaceuticals Inc; Pfizer Inc.; Portola Pharmaceuticals; Vifor Pharma|
|Craig Beavers, PharmD
|Nothing to disclose|
Leo Buckley, PharmD
|Consultant/Advisor: Esperion Therapeutics, Inc.; Kiniksa Pharmaceuticals|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of continuing pharmacy education credit (UAN # JA4008190-0000-21-025-H04-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from the Boehringer Ingelheim/Lilly alliance.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and the Boehringer Ingelheim/Lilly alliance do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].